Sign In
Buy IMUX
$14.17
-0.470 (-3.21%)
At Close: Jun 03, 2026
Immunic advances ‘potentially groundbreaking' MS therapy vidofludimus calcium during Q1
09:39am, Wednesday, 08'th May 2024
Immunic Inc (NASDAQ:IMUX) continued to advance its clinical programs for its lead drug asset, nuclear receptor related 1 (Nurr1) activator vidofludimus calcium (IMU-838), during the first quarter of 2
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
06:30am, Wednesday, 08'th May 2024
– Substantially Bolstered Balance Sheet Through a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tran
Immunic to Participate in Investor and Scientific Conferences in May
06:30am, Monday, 06'th May 2024
NEW YORK , May 6, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
06:30am, Wednesday, 01'st May 2024
– Webcast to be Held at 8:00 am ET on May 8, 2024 – NEW YORK , May 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally adminis
Immunic publishes extended data from Phase 2 MS trial in peer-reviewed journal
08:52am, Tuesday, 30'th Apr 2024
Immunic Inc (NASDAQ:IMUX) has published extended data from its Phase 2 EMPhASIS trial of its lead asset vidofludimus calcium in relapsing-remitting Multiple Sclerosis (RRMS) in the peer-reviewed journ
– 30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks – – Improvements in Serum Neuro
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
06:30am, Thursday, 04'th Apr 2024
NEW YORK , April 4, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflamma
Immunic granted patent for specific polymorph of vidofludimus calcium in US
08:36am, Wednesday, 20'th Mar 2024
Immunic Inc (NASDAQ:IMUX) has received a Notice of Allowance for a composition-of-matter patent covering a specific polymorph of vidofludimus calcium, which is being advanced as a treatment for chroni
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
06:30am, Wednesday, 20'th Mar 2024
– Patent Will Also Cover a Related Method of Production of the Material – – Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis – – Multilayered Intellectual Pro
Immunic to Participate in Investor and Scientific Conferences in March
06:30am, Thursday, 07'th Mar 2024
NEW YORK , March 7, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammat
Immunic to present data for lead asset vidofludimus calcium from Phase 2 MS and COVID-19 trials
08:42am, Thursday, 29'th Feb 2024
Immunic Inc (NASDAQ:IMUX) announced that it will present data from its Phase 2 CALLIPER and CALVID-1 clinical trials of its lead asset vidofludimus calcium (IMU-838) at the Americas Committee for Trea
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
06:30am, Thursday, 29'th Feb 2024
NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflamma
Immunic expects financial stability through 2025 as MS clinical programs advance
09:46am, Thursday, 22'nd Feb 2024
Biotechnology company Immunic Inc (NASDAQ:IMUX) disclosed its financial results for the fourth quarter and year ended December 31, 2023, alongside significant clinical advancements, marking a pivotal
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
06:30am, Thursday, 22'nd Feb 2024
– Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025 Based on Init
Immunic's cutting-edge MS treatment approach: insights from CEO Dr Daniel Vitt
10:31am, Thursday, 15'th Feb 2024
The journey toward effective therapies for patients with multiple sclerosis (MS) is marked by persistent challenges. Despite advancements in addressing relapses, the specter of disability progression
